Does IV Robaxin Cause Decreased GI Motility?
No, IV methocarbamol (Robaxin) does not cause decreased gastrointestinal motility based on available evidence. The FDA-approved prescribing information for IV Robaxin does not list decreased GI motility, constipation, or any motility-related effects among its adverse reactions 1.
Evidence from FDA Drug Label
The official FDA label for IV Robaxin lists the following gastrointestinal adverse reactions: dyspepsia, jaundice (including cholestatic jaundice), nausea, and vomiting 1. Notably absent from this list are any effects on GI motility, constipation, or intestinal transit time.
Mechanism of Action
Methocarbamol is described as a central nervous system (CNS) depressant with sedative and musculoskeletal relaxant properties 1. Its mechanism involves:
- Blocking muscular Nav 1.4 sodium channels in skeletal muscle 2
- CNS depression without direct effects on smooth muscle of the GI tract
- No anticholinergic properties that would typically slow GI motility
Comparison to Drugs That DO Affect GI Motility
The evidence clearly identifies drugs that genuinely decrease GI motility, and methocarbamol is not among them:
Drugs that inhibit intestinal motility include:
- Opioids (loperamide, codeine, diphenoxylate) 3
- Anticholinergics (dicycloverine, propantheline, hyoscine butylbromide) 4
- Tricyclic antidepressants 5
- Calcium channel blockers 4
- Clonidine 4
These agents work through specific mechanisms (opioid receptors, muscarinic receptors, calcium channels) that directly affect intestinal smooth muscle or the enteric nervous system 4.
Clinical Context
When guidelines discuss drugs affecting GI motility in various conditions (gastroparesis, short bowel syndrome, intestinal dysmotility), methocarbamol is never mentioned 3, 4, 3, 5, 6. This absence is significant given the comprehensive nature of these reviews.
Important Caveat
While methocarbamol itself does not decrease GI motility, it is often prescribed alongside opioid analgesics for musculoskeletal pain. If a patient on IV Robaxin develops constipation or decreased GI motility, the culprit is almost certainly the concurrent opioid medication, not the methocarbamol 4, 3.
The research confirms that opioids profoundly inhibit intestinal motility and delay gastric emptying 7, 8, which has significant clinical and therapeutic implications. This effect is well-documented and consistent across the literature.